The GMRF Clinical Trials Unit is currently recruiting for the following clinical trials in genitourinary cancer:
PROTOCOL: BGB-A317-3111-10188-101 (PI: Jeffrey Goh) (PART E (OVARIAN) ONLY)
Protocol Title: A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined with Zanubrutinib in Patients with Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors.
Lay Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Click here for more information
Protocol: D361EC00001 (CAPitello-280), PI Dr Ken O’Byrne
Protocol title: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lay title: Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)